Extracellular dopamine induces the oxidative toxicity of SH-SY5Y cells

Synapse

Volumn 62, Issue 11, 2008, Pages 797-803

  Jiang, Yuhua ^a,b   Pei, Lin ^a   Li, Shupeng ^a   Wang, Min ^a   Liu, Fang ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b SHANDONG UNIVERSITY   (China)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Apoptosis; Ascorbic acid; Dopamine; Oxidative stress

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ASCORBIC ACID; DOPAMINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GLUTATHIONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN P53; SIGNAL PEPTIDE; VANOXERINE;

APOPTOSIS; ARTICLE; AUTOOXIDATION; CELL DEATH; CELL LINE; CELL METABOLISM; CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; DOSE RESPONSE; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; NEUROBLASTOMA; NEUROPROTECTION; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

APOPTOSIS; ASCORBIC ACID; BIOLOGICAL TRANSPORT, ACTIVE; CELL DEATH; CELL LINE, TUMOR; CYTOTOXINS; DEHYDROASCORBIC ACID; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SPACE; GLUTATHIONE; HUMANS; NEUROBLASTOMA; NEURONS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 52249094382     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20554     Document Type: Article

References (38)

1. Andringa G, Stoof JC, Cools AR. 1999. Sub-chronic administration of the dopamine D(1) antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: Stable therapeutic effects and wearing-off dyskinesia. Psychopharmacology (Berl) 146:328-434.
2. Banday AA, Fazili FR, Lokhandwala MF. 2007. Oxidative stress causes renal dopamine D1 receptor dysfunction and hypertension via mechanisms that involve nuclear factor-kappaB and protein kinase C. J Am Soc Nephrol 18:1446-1457.
3. Barnham KJ, Masters CL, Bush AI. 2004. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3:205-214.
4. Bindoli A, Rigobello MP, Deeble DJ. 1992. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic Biol Med 13:391-405.
5. Chen J, Rusnak M, Luedtke RR, Sidhu A. 2004. D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. J Biol Chem 279:39317-39330.
6. Chiasson K, Daoust B, Levesque D, Martinoli MG. 2006. Dopamine D2 agonists, bromocriptine and quinpirole, increase MPP+ - induced toxicity in PC12 cells. Neurotox Res 10:31-42.
7. Cohen G. 1983. The pathobiology of Parkinson's disease: Biochemical aspects of dopamine neuron senescence. J Neural Transm Suppl 19:89-103.
8. Fasano M, Bergamasco B, Lopiano L. 2006. Modifications of the iron-neuromelanin system in Parkinson's disease. J Neurochem 96:909-916.
9. Gabby M, Tauber M, Porat S, Simantov R. 1996. Selective role of glutathione in protecting human neuronal cells from dopamine-induced apoptosis. Neuropharmacology 35:571-578.
10. Gangopadhyay S, Jalali F, Reda D, Peacock J, Bristow RG, Benchimol S. 2002. Expression of different mutant p53 transgenes in neuroblastoma cells leads to different cellular responses to genotoxic agents. Exp Cell Res 275:122-131.
11. Goedert M. 2001. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2:492-501.
12. Guaiquil VH, Vera JC, Golde DW. 2001. Mechanism of vitamin C inhibition of cell death induced by oxidative stress in glutathione-depleted HL-60 cells. J Biol Chem 276:40955-40961.
13. Hanrott K, Gudmunsen L, O'Neill MJ, Wonnacott S. 2006. 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J Biol Chem 281:5373-5382.
14. Hastings TG, Lewis DA, Zigmond MJ. 1996. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci USA 93:1956-1961.
15. Heikkila RE, Manzino L. 1987. Ascorbic acid, redox cycling, lipid peroxidation, and the binding of dopamine receptor antagonists. Ann NY Acad Sci 498:63-76.
16. Hemilä H, Roberts P, Wikström M. 1984. Activated polymorphonuclear leucocytes consume vitamin C. FEBS Lett 178:25-30.
17. Jenner P, Schapira AH, Marsden CD. 1992. New insights into the cause of Parkinson's disease. Neurology 42:2241-2250.
18. Kopin IJ. 1985. Catecholamine metabolism: Basic aspects and clinical significance. Pharmacol Rev 37:333-364.
19. Lai CT, Yu PH. 1997. Dopamine- and L-beta-3,4- dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem Pharmacol 53:363-372.
20. Larouche A, Berube P, Sarret P, Grignon S. 2008. Subacute H2O2, but not poly(IC), upregulates dopamine D2 receptors in retinoic acid differentiated SH-SY5Y neuroblastoma. Synapse 62:70-73.
21. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
22. Maguire-Zeiss KA, Short DW, Federoff HJ. 2005. Synuclein, dopamine and oxidative stress: Co-conspirators in Parkinson's disease? Brain Res Mol Brain Res 134:18-23.
23. Manáková S, Puttonen KA, Raasmaja A, Männistö PT. 2004. The roles of dopamine transporter and Bcl-2 protein in the protection of CV1-P cells from 6-OHDA-induced toxicity. Toxicol Lett 154:117-123.
24. Nakamura K, Wang W, Kang UJ. 1997. The role of glutathione in dopaminergic neuronal survival. J Neurochem 69:1850-1858.
25. Nishikimi M. 1975. Oxidation of ascorbic acid with superoxide anion generated by the xanthine-xanthine oxidase system. Biochem Biophys Res Commun 63:463-468.
26. Offen D, Ziv I, Sternin H, Melamed E, Hochman A. 1996. Prevention of dopamine-induced cell death by thiol antioxidants: Possible implications for treatment of Parkinson's disease. Exp Neurol 141:32-39.
27. Owen AD, Schapira AH, Jenner P, Marsden CD. 1996. Oxidative stress and Parkinson's disease. Ann NY Acad Sci 786:217-223.
28. Pedrosa R, Soares-da-Silva P. 2002. Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4- dihydroxyphenylalanine (L-DOPA) and dopamine. Br J Pharmacol 137:1305-1313.
29. Pileblad E, Magnusson T, Fornstedt B. 1989. Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depleting action of 6-hydroxydopamine in rat striatum. J Neurochem 52:978-980.
30. Pileblad E, Slivka A, Bratvold D, Cohen G. 1988. Studies on the autoxidation of dopamine: Interaction with ascorbate. Arch Biochem Biophys 263:447-452.
31. Rabinovic AD, Hastings TG. 1998. Role of endogenous glutathione in the oxidation of dopamine. J Neurochem 71:2071-2078.
32. Rochet JC, Outeiro TF, Conway KA, Ding TT, Volles MJ, Lashuel HA, Bieganski RM, Lindquist SL, Lansbury PT. 2004. Interactions among alpha-synuclein, dopamine, and biomembranes: Some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci 23:23-34.
33. Sakagami H, Satoh K. 1997. Prooxidant action of two antioxidants: Ascorbic acid and gallic acid. Anticancer Res 17:221-224.
34. Song JH, Shin SH, Ross GM. 2001. Oxidative stress induced by ascorbate causes neuronal damage in an in vitro system. Brain Res 895:66-72.
35. Stokes AH, Lewis DY, Lash LH, Jerome WG III, Grant KW, Aschner M, Vrana KE. 2000. Dopamine toxicity in neuroblastoma cells: Role of glutathione depletion by L-BSO and apoptosis. Brain Res 858:1-8.
36. Tukov FF, Rimoldi JM, Matthews JC. 2004. Characterization of the role of glutathione in repin-induced mitochondrial dysfunction, oxidative stress and dopaminergic neurotoxicity in rat pheochromocytoma (PC12) cells. Neurotoxicology 25:989-999.
37. Velez-Pardo C, Jimenez Del Rio M, Verschueren H, Ebinger G, Vauquelin G. 1997. Dopamine and iron induce apoptosis in PC12 cells. Pharmacol Toxicol 80:76-84.
38. Wüllner U, Löschmann PA, Schulz JB, Schmid A, Dringen R, Eblen F, Turski L, Klockgether T. 1996. Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones. Neuroreport 7:921-923.